Patent intelligence · US
US 12054487
Muscarinic acetylcholine M1 receptor antagonists
Muscarinic acetylcholine M1 receptor antagonists
Patent details — US 12054487
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2024
- Expiration
- Aug 1, 2044
- Applicant
- Contineum Therapeutics, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/136, A61K31/137, A61K31/198
Quick answer
US 12054487 (Muscarinic acetylcholine M1 receptor antagonists) is held by Contineum Therapeutics, Inc.. Status: granted. Granted Aug 6, 2024. Expires Aug 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Contineum Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/136, A61K31/137, A61K31/198, A61K31/277, A61K31/498
More from Contineum Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12054487?
US 12054487 (Muscarinic acetylcholine M1 receptor antagonists) is held by Contineum Therapeutics, Inc.. Status: granted. Granted Aug 6, 2024. Expires Aug 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12054487?
Contineum Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12054487 expire?
Our index shows an expiration date of Aug 1, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.